Marquez-Nostra BV - Search Results

1

Imaging of HER2 with [⁸⁹Zr]pertuzumab in Response to T-DM1 Therapy.

Massicano AVF, Lee S, Crenshaw BK, Aweda TA, El Sayed R, Super I, Bose R, Marquez-Nostra BV, Lapi SE. Massicano AVF, et al. Among authors: marquez nostra bv. Cancer Biother Radiopharm. 2019 May;34(4):209-217. doi: 10.1089/cbr.2018.2654. Epub 2019 Jan 24. Cancer Biother Radiopharm. 2019. PMID: 30676778 Free PMC article.

2

[⁸⁹Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer.

Laforest R, Lapi SE, Oyama R, Bose R, Tabchy A, Marquez-Nostra BV, Burkemper J, Wright BD, Frye J, Frye S, Siegel BA, Dehdashti F. Laforest R, et al. Among authors: marquez nostra bv. Mol Imaging Biol. 2016 Dec;18(6):952-959. doi: 10.1007/s11307-016-0951-z. Mol Imaging Biol. 2016. PMID: 27146421 Free PMC article. Clinical Trial.

3

Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent.

Marquez-Nostra BV, Lee S, Laforest R, Vitale L, Nie X, Hyrc K, Keler T, Hawthorne T, Hoog J, Li S, Dehdashti F, Ma CX, Lapi SE. Marquez-Nostra BV, et al. Oncotarget. 2017 Nov 1;8(61):104303-104314. doi: 10.18632/oncotarget.22228. eCollection 2017 Nov 28. Oncotarget. 2017. PMID: 29262642 Free PMC article.

4

Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with ⁸⁹Zr in Human Lymphoma Xenografts.

Yoon JT, Longtine MS, Marquez-Nostra BV, Wahl RL. Yoon JT, et al. Among authors: marquez nostra bv. J Nucl Med. 2018 Aug;59(8):1219-1224. doi: 10.2967/jnumed.117.203299. Epub 2018 Jan 18. J Nucl Med. 2018. PMID: 29348316 Free PMC article.

5

Targeting HER2 in Nuclear Medicine for Imaging and Therapy.

Massicano AVF, Marquez-Nostra BV, Lapi SE. Massicano AVF, et al. Among authors: marquez nostra bv. Mol Imaging. 2018 Jan-Dec;17:1536012117745386. doi: 10.1177/1536012117745386. Mol Imaging. 2018. PMID: 29357745 Free PMC article. Review.

6

Evaluation of [⁸⁹Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer.

Dehdashti F, Wu N, Bose R, Naughton MJ, Ma CX, Marquez-Nostra BV, Diebolder P, Mpoy C, Rogers BE, Lapi SE, Laforest R, Siegel BA. Dehdashti F, et al. Among authors: marquez nostra bv. Breast Cancer Res Treat. 2018 Jun;169(3):523-530. doi: 10.1007/s10549-018-4696-z. Epub 2018 Feb 13. Breast Cancer Res Treat. 2018. PMID: 29442264 Free PMC article.

7

Development of [⁸⁹Zr]ZrDFO-amivantamab bispecific to EGFR and c-MET for PET imaging of triple-negative breast cancer.

Cavaliere A, Sun S, Lee S, Bodner J, Li Z, Huang Y, Moores SL, Marquez-Nostra B. Cavaliere A, et al. Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):383-394. doi: 10.1007/s00259-020-04978-6. Epub 2020 Aug 8. Eur J Nucl Med Mol Imaging. 2021. PMID: 32770372 Free PMC article.

8

[89Zr]ZrDFO-CR011 PET Correlates with Response to Glycoprotein Nonmetastatic Melanoma B-targeted Therapy in Triple-negative Breast Cancer.

Lee S, Cavaliere A, Gallezot JD, Keler T, Michelhaugh SK, Belitzky E, Liu M, Mulnix T, Maher SE, Bothwell ALM, Li F, Phadke M, Mittal S, Marquez-Nostra B. Lee S, et al. Mol Cancer Ther. 2022 Mar 1;21(3):440-447. doi: 10.1158/1535-7163.MCT-21-0590. Mol Cancer Ther. 2022. PMID: 35027482 Free PMC article.

9

Intrathecal delivery of nanoparticle PARP inhibitor to the cerebrospinal fluid for the treatment of metastatic medulloblastoma.

Khang M, Lee JH, Lee T, Suh HW, Lee S, Cavaliere A, Rushing A, Geraldo LH, Belitzky E, Rossano S, de Feyter HM, Shin K, Huttner A, Roussel MF, Thomas JL, Carson RE, Marquez-Nostra B, Bindra RS, Saltzman WM. Khang M, et al. Sci Transl Med. 2023 Nov;15(720):eadi1617. doi: 10.1126/scitranslmed.adi1617. Epub 2023 Nov 1. Sci Transl Med. 2023. PMID: 37910601 Free PMC article.

10

ImmunoPET Imaging Identifies the Optimal Timepoint for Combination Therapy in Xenograft Models of Triple-Negative Breast Cancer.

Li Z, Belitzky E, Blaha O, Cavaliere A, Katz SR, Aboian M, Melegari L, Rajabimoghadam K, Kurpiewski S, Zhu X, Marquez-Nostra B. Li Z, et al. Cancers (Basel). 2023 Mar 3;15(5):1589. doi: 10.3390/cancers15051589. Cancers (Basel). 2023. PMID: 36900378 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

15 results

Search Page